Literature DB >> 3198937

Human T lymphotropic virus type I antibody patterns: evidence of difference by age and risk group.

G Agius1, R J Biggar, S S Alexander, D J Waters, J E Drummond, E L Murphy, S H Weiss, P H Levine, W A Blattner.   

Abstract

Detection of human T lymphotropic virus type I (HTLV-I) antibody was assessed on 368 sera from subjects with different clinical features and from different parts of the world. Enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay for purified p24 antibodies (p24-RIA) used as screening tests agreed in 88.7% of the sera. The results from 247 selected sera were compared with western blot (WB). WB was reactive in sera five to 25 times more dilute than the last positive ELISA or p24-RIA, but different WB batches varied in sensitivity. ELISA was more sensitive than p24-RIA, and p24-RIA was more specific than ELISA. Indeterminate WB interpretations were common (25.5%). Most seropositive intravenous drug abusers had unusually strong p24 bands by WB. Among healthy individuals, positive WB reactivity increased with age, whereas indeterminate reactivity declined (P = .034). Thus, more-sensitive and -specific HTLV-I antibody tests are needed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3198937     DOI: 10.1093/infdis/158.6.1235

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  HTLV-I antibody studies in villagers in East Sepik Province, Papua New Guinea.

Authors:  R C Sanders; A Levin; G Anian; I Webber; H Lee; P Swanson; A Diwan; R Desowitz; W A Blattner; M P Alpers
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  HTLV-I, HIV-1 and HIV-2 seroprevalences in Guadeloupe, French West Indies.

Authors:  G Agius; V Vaillant; G Dindinaud; M Bazillou; J F Zagury; V Kolesnitchenko; M Castets
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

3.  Comparison of immunofluorescence, particle agglutination, and enzyme immunoassays for detection of human T-cell leukemia virus type I antibody in African sera.

Authors:  M Verdier; F Denis; G Leonard; A Sangare; S Patillaud; M Prince-David; M Essex
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome.

Authors:  E DeFreitas; B Hilliard; P R Cheney; D S Bell; E Kiggundu; D Sankey; Z Wroblewska; M Palladino; J P Woodward; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  HTLV-II infection in the Western United States.

Authors:  B Hjelle
Journal:  West J Med       Date:  1994-06

6.  Human T-cell lymphotropic virus types I and II infections in patients with leukaemia/lymphoma and in subjects with sexually transmitted diseases in Nigeria.

Authors:  O D Olaleye; C C Ekweozor; Z L Li; I E Opala; Z Sheng; T N Onyemenem; S Rasheed
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera.

Authors:  Scott A Tenenbaum; Cindy A Morris; Steve S Alexander; Harris E McFerrin; Robert F Garry; Cindy A Leissinger
Journal:  Virol J       Date:  2005-08-17       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.